EcoDrugPlus

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSAMXG00000031787
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSAMXG00000039164
Gene Symbol: LOC103047601
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSAMXG00000034204
Gene Symbol: HTR5A
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSAMXG00000012315
Gene Symbol: HTR6
3 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSAMXG00000040600
Gene Symbol: HTR7
3 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSAMXG00000030881
Gene Symbol: LOC103047485
3 Cross references
382 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSAMXG00000031758
Gene Symbol: LOC103040128
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSAMXG00000032155
Gene Symbol: LOC103021491
3 Cross references
338 Possible Orthologues:

60s Ribosomal Protein L35a

Ensembl ID : ENSAMXG00000041448
Gene Symbol: LOC111189478
3 Cross references
511 Possible Orthologues:

60s Ribosomal Protein L5-A

Ensembl ID : ENSAMXG00000006688
Gene Symbol: LOC103029008
3 Cross references
447 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSAMXG00000004222
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSAMXG00000034241
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).